Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome – Submitted Application to Japanese MHLW ...
Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome - Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW Confirme ...
Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...
The Body Optimist on MSN
Suffering from a skin condition, she uses makeup as a tool for self-acceptance
Born with Netherton syndrome, a condition that affects the skin's appearance and gives the illusion of sunburned flesh, ...
Azitra, Inc. ("Azitra" or the "Company") , a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the ...
Full-year 2026 ORLADEYO revenue guidance is maintained at $625 million to $645 million, assuming the pediatric manufacturing ...
The winding road of BioCryst Pharmaceuticals’ avoralstat has come to an end. | The company announced it has concluded ...
Please note, this event is being recorded. I would now like to turn the conference over to Nick Wilder. Please go ahead. Good morning, and welcome to BioCryst's First Quarter 2026 Corporate Update and ...
Detailed price information for Biocryst Pharma Inc (BCRX-Q) from The Globe and Mail including charting and trades.
RESEARCH TRIANGLE PARK, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended March 31, 2026, and provided a ...
Detailed price information for Quoin Pharmaceuticals Ltd ADR (QNRX-Q) from The Globe and Mail including charting and trades.
Megan and Harrison's dad, James, are his full-time carers and the family are supported by Alder Hey Children's Hospital. She ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results